Zimmer Biomet Holdings (ZBH) Tops Q4 EPS by 5c, Beats on Revenue; Offers FY23 Guidance

Zimmer Biomet Holdings (NYSE: ZBH) reported Q4 EPS of $1.88, $0.05 better than the analyst estimate of $1.83. Revenue for the quarter came in at $1.83 billion versus the consensus estimate of $1.76 billion.

GUIDANCE:

Zimmer Biomet Holdings sees FY2023 EPS of $6.95-$7.15, versus the consensus of $6.98.

For earnings history and earnings-related data on Zimmer Biomet Holdings (ZBH) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Geberit AG (GEBN:SW) (GBERY) PT Raised to CHF712 at Jefferies
• UiPath Inc. (PATH) Reports In-Line Q2 EPS; offers guidance